Bioqual (OTCMKTS:BIOQ – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, Zacks reports. The company had revenue of $10.15 million for the quarter. Bioqual had a negative return on equity of 12.04% and a negative net margin of 10.29%.
Bioqual Stock Performance
Shares of OTCMKTS:BIOQ remained flat at $30.64 during midday trading on Friday. The firm’s 50-day moving average is $32.79 and its 200-day moving average is $33.63. Bioqual has a 1 year low of $30.64 and a 1 year high of $43.55. The company has a market cap of $27.27 million, a price-to-earnings ratio of -6.60 and a beta of -0.10.
About Bioqual
Bioqual, Inc is a biomedical research and contract research organization based in Rockville, Maryland. The company provides preclinical research services to pharmaceutical and biotechnology companies, government agencies, and other organizations involved in the development of medical products.
Its work focuses primarily on infectious diseases, vaccines, therapeutics, and diagnostics. Bioqual conducts laboratory and animal-model studies designed to evaluate the safety, efficacy, immunology, virology, and pharmacology of potential treatments and preventive products.
Read More
- Five stocks we like better than Bioqual
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
- Chefs’ Warehouse Has Rallied 76%—Can the Stock Keep Climbing?
Receive News & Ratings for Bioqual Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioqual and related companies with MarketBeat.com's FREE daily email newsletter.
